1. Scrip
  2. >>Digital Technologies
  3. >>AI

For GSK R&D Head Hal Barron 'There's No Place Like Home' For Seeding Innovation

 
• By Sten Stovall

GSK President R&D Hal Barron came to a big investor meeting with one bit of tangible news, a collaboration with consumer genetics leader 23andMe. Barron and CEO Emma Walmsley talked about the deal and Barron's California headquarters in a media briefing. 

SC1807_San Francisco_518796124_1200.jpg
Barron Will Orchestrate GSK's R&D Efforts From Tech-Savvy San Francisco • Source: Shutterstock

For Hal Barron, a Californian who now heads global R&D for GlaxoSmithKline PLC, there's no place like home when it comes to the convergence of science and technology -- and his view has the full backing of his UK-based CEO, Emma Walmsley. The chief executive said she believes having Barron based in the San Francisco Bay area will help advance medical research and promote the culture change GSK needs.

Walmsley and Barron held a media briefing July 25, just ahead of presenting a new R&D strategy to investors and the same day as the company's second quarter financial results

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Menarini’s APAC CEO On Harnessing Digital Channels, RWE And BD Engine

 
• By Anju Ghangurde

In the final part of an interview with Scrip, Menarini’s Asia-Pacific CEO talks about the group’s digital capabilities, including their impact on a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The Italian company is also revving up its business development and alliance engine.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.

Isomorphic Adds To Growing AI War Chest With First External Funding Round

 
• By Alaric DeArment

The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.

More from Digital Technologies

How Big Pharma Is Redefining, Scaling India GCCs Amid Tech Advances

 
• By Anju Ghangurde

Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?

Generative AI In Drug Discovery And India’s Potential To Leapfrog

 
• By Vibha Ravi

Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process

With Fabhalta’s C3G Approval, Now Novartis Has To Find The Patients

 
• By Alaric DeArment

Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.